AbbVie Inc (ABBV)vsHong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
HKPD
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
$0.63
-3.85%
HEALTHCARE · Cap: $15.52M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 373743% more annual revenue ($61.16B vs $16.36M). ABBV leads profitability with a 6.9% profit margin vs -4.3%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
HKPD
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+81.4%
Fair Value
$4.29
Current Price
$0.63
$3.67 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 3.0%
ROE of -13.4% — below average capital efficiency
Revenue declined 35.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : HKPD
The strongest argument for HKPD centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : HKPD
The primary concerns for HKPD are Market Cap, Operating Margin, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while HKPD is a turnaround play — different risk/reward profiles.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 22/100). HKPD offers better value entry with a 81.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Hong Kong Pharma Digital Technology Holdings Limited is a pioneering company at the intersection of biotechnology and digital healthcare, focusing on the integration of cutting-edge technology with pharmaceutical services to enhance patient outcomes and streamline healthcare delivery. Leveraging advanced digital solutions and data analytics, the company optimizes drug development processes and improves operational efficiencies, positioning itself as a critical player in the evolving healthcare landscape. With a strong commitment to health technology advancement and the cultivation of strategic alliances, Hong Kong Pharma is poised to meet the demands of both domestic and global markets while driving innovation across its pharmaceutical service offerings.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?